Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating Investment IncomeNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Quantum Biopharma (QNTM) Research & Development (2020 - 2025)

Quantum Biopharma's Research & Development history spans 6 years, with the latest figure at $70404.0 for Q4 2025.

  • On a quarterly basis, Research & Development fell 56.07% to $70404.0 in Q4 2025 year-over-year; TTM through Dec 2025 was $2.8 million, a 40.74% increase, with the full-year FY2025 number at $2.8 million, down 54.58% from a year prior.
  • Research & Development hit $70404.0 in Q4 2025 for Quantum Biopharma, down from $495223.0 in the prior quarter.
  • Over the last five years, Research & Development for QNTM hit a ceiling of $3.6 million in Q2 2021 and a floor of $32985.0 in Q3 2023.
  • Historically, Research & Development has averaged $968402.8 across 5 years, with a median of $646999.5 in 2024.
  • The widest YoY moves for Research & Development: up 2158.0% in 2024, down 93.07% in 2024.
  • Tracing QNTM's Research & Development over 5 years: stood at $3.6 million in 2021, then crashed by 74.06% to $937052.0 in 2022, then crashed by 96.48% to $32985.0 in 2023, then soared by 385.86% to $160260.0 in 2024, then tumbled by 56.07% to $70404.0 in 2025.
  • Business Quant data shows Research & Development for QNTM at $70404.0 in Q4 2025, $495223.0 in Q3 2025, and $549197.0 in Q2 2025.